On April 8th the COMETA project kick-off meeting will be held in Rome

together with Enea and Campus Bio-Medico University of Rome, at the headquarters of Danesi Caffè Spa

The COMETA project (Quality testing of organoleptic properties of COffee blends via genetic and METAbolic fingerprinting) co-funded by the Lazio Region, is united in partnership, under the coordination of Danesi Caffè SpA, ENEA, the Campus Biomedico University of Rome and Genechron Srl, with the collaboration of CREA-Food and Nutrition and of the Italian Federation of Doctors in Agricultural Sciences and Forest Sciences (FIDAF).
The COMETA project will develop new tools to support the complex and skillful process of coffee roasting, in the presence of a growing diversification of varieties and of the biochemical composition of the raw material, also induced by the effects of climate change.

Genechron selected among the projects that will participate in the Bio In Italy roadshow

Bio In Italy Investment is a forum organized by Assobiotec and Intesa Sanpaolo Innovation Center. At its eleventh edition it is now a reference event for innovation in biotechnologies and life sciences in Italy and uses regional partners for the scouting of the best talents on the territory.

Three of the eight innovative projects were selected, including Genechron, as an innovative startup operating in the molecular biomarker sector for hepatotoxicity and epilepsy. All of them concluded the startup journey with Lazio Innova and were presented at the call of the Life Sciences and Circular Bio Economy sector last December.

The teams will participate at the bootcamp phase at the Intesa San Paolo Innovation Center in Turin, preparatory to the final with investors and Business Angels in April, at the Cariplo Factory in Milan.

Genechron participates in the COMETA project (Qualitative tests of the organoleptic properties of COffee blends through genetic and METAbolic fingerprinting) co-funded by Lazio Innova through the Key Enabling Technologies call as an Integrated Project in the specialized area Life Sciences Sector

The project partnership is coordinated by the company Danesi Caffè SpA and makes effective use of ENEA and Rome's Campus Biomedical University as Research Bodies.

The COMETA project is aimed at creating an electronic multisensory system capable of detecting specific chemical compounds in the gas phase that are released during the roasting process, from whose analysis it is possible to accurately identify optimal process parameters, which originate those particular properties organoleptic characteristics of which the drink in the cup is characterized.

The project will perform a genetic fingerprinting of the species and of which the Danish mixtures are composed and, through the determination of the metabolites that occur during the roasting process, these compounds will be associated with their genetic origin.

The COMETA project therefore intends to transfer, within an electronic system to be used in the production process, the centenary wisdom of a company of excellence in coffee production in Italy.

Overall, for the COMETA project, Genechron had access to costs of € 282,534.27, for which grants amounting to € 176,812.89 were granted for the POR FESR LAZIO 2014 - 2020 Public Notice "KETS enabling technologies".

Genechron among the winners of the Lazio Region announcement "Contributions to support the processes of internationalization of Lazio's SMEs"

With the proposal called "Internationalization of miRNA biomarket essay services in the area of ‚Äč‚Äčliverdisease" Genechron was among the winning companies of the Lazio Region Notice "Contributions to support the processes of internationalization of Lazio's SMEs" Life 2020 - POR FESR LAZIO 2014 - 2020.

The project aims to develop a new international market, aimed at providing new services for the analysis of biomarkers.

In particular, the following activities will be carried out:

- Participation in trade fairs and relevant business events abroad
- Acquisition of strategic support for the preparation of a business penetration plan
- Acquisition of consultancy support for the search for foreign operators and assistance for organizing business meetings
- Quality certification activities
- Acquisition of Advisory Support for the reporting of the activities of the Internationalization project
- Intangible investments for internationalization

The activities of the biotechnology sector are included in the regional Smart Specialization Strategy (S3).

Overall, an investment of € 76.651,69 was admitted for the project, against which € 30.660,68 concessions were granted for the POR FESR Lazio 2014 - 2020 funds.

The DIHETOX project, winner of the POR FESR Lazio 2014-2020 announcement

The DIHETOX project, presented by Genechron in collaboration with the CLSN Center of the Italian Institute of Technology in Rome, is among the winning projects of the POR FESR Lazio Announcement 2014 - 2020 Public Notice "LIFE 2020" Integrated Projects of the Lazio Region.

The DIHETOX project arises from the need to identify and validate RNA biomarkers (miRNA or mRNA) able to early detect the presence of drug-induced liver damage (DILI, Drug-Induced Liver Injury) or to detect in a precise way possible interactions between pharmacological treatments.

The analysis of potential toxic effects of new drugs is necessary in the initial stages of drug development: biomarkers allow to detect the effects accurately, both in the liver and in the other organs (heart, kidneys).

The DIHETOX project will act on two fronts that have interconnected objectives:

  • the first will concern the development and validation of an assay for the early evaluation of non-specific hepatotoxicity or linked to specific drugs / compounds.
  • the second will concern the development and optimization of an assay that can be applied for the evaluation of the interaction between drugs and will determine whether the simultaneous intake of multiple drugs reduces the pharmacological effects or decreases (or increases) the toxicity of such drugs. 

Therefore, the tests will not only allow identification of any hepatotoxic or cytotoxic effects of the drugs / compounds analyzed, but will give information on the effects of the interaction of several drugs in the case of poly-pharmacotherapy.

The project will be completed within half of 2019 and will allow the realization of these tests, which will, after a further phase of testing and screening on a patient population, put on the market of Diagnostic Medical and Pre-Clinical Trials of new drugs.

Overall, for the DIHETOX project an investment amounting to € 903,128.61 was admitted, for which grants amounting to € 658,282.82 were granted for the POR FESR Lazio 2014 - 2020.

  • 1
  • 2